Ensartinib (X-396)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Ensartinib (X-396), covering 2025-10-14 to 2025-10-14. Get the full timeline:
Most recent: Clinical Trial Update: eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients [Phase 3]